Copyright
©The Author(s) 2024.
World J Hepatol. Jul 27, 2024; 16(7): 1009-1017
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1009
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1009
Figure 2 Improvement rates (%) of alanine aminotransferase and aspartate aminotransferase to < 35 (male)/25 (female) and < 30 (male)/19 (female), aspartate aminotransferase to platelet ratio index to < 0.
5 and fibrosis-4 to < 1.45 at baseline and after switching week 144. A and B: There was a great improvement rates of alanine aminotransferase and aspartate aminotransferase to normalization (A) and improvement rates of aspartate aminotransferase to platelet ratio index to < 0.5 and fibrosis-4 to < 1.45 (B) after tenofovir disoproxil fumarate switching to tenofovir alafenamide for 144 weeks, compared to baseline. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FIB-4: Fibrosis-4; APRI: Aspartate aminotransferase to platelet ratio index.
- Citation: Huynh T, Bui DM, Zhou TX, Hu KQ. Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years. World J Hepatol 2024; 16(7): 1009-1017
- URL: https://www.wjgnet.com/1948-5182/full/v16/i7/1009.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i7.1009